Detalhe da pesquisa
1.
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Lancet Haematol
; 7(11): e808-e815, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010817